This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Media
-
Dr Daniel Tillett joins Race Board
17 September 2019 – Race Oncology Limited (ASX: RAC) is pleased to announce that prominent biotechnology investor and substantial Race shareholder, Dr Daniel Tillett, has today joined the Board of Directors of Race Oncology Ltd. Dr Daniel Tillett is the founder and CEO of successful Sydney-based biotechnology company, Nucleics, which specialises in DNA sequencing and Genomics.…
-
Prominent biotech investor leads investment in Race
Race Oncology Limited is pleased to announce the successful completion of a $1.45 million placement, led by prominent biotechnology investor Dr Daniel Tillett. The placement comprised 21.9 million new ordinary shares at an issue price of $0.066 (6.6 cents) per share. The issue price represented a 10 per cent premium over the 30-day VWAP (volume-weighted…
-
Race announces additional US Patent for Zantrene
Race Oncology has announced it has secured a new patent on its cancer drug, Zantrene®, from the United States Patent and Trademarks Office (USPTO). This is Race’s third patent granted on Zantrene in the United States. “The new US patent allows additional claims around the use of Bisantrene in combination with other drugs for treating…
-
Race’s Israel trial treats first patient with Bisantrene
Race Oncology is pleased to announce it has successfully completed treatment on its first patient at the Sheba Medical Center in Israel as part of its Bisantrene trial at the facility. The patient diagnosed with relapsed/refractory Acute Myeloid Leukaemia (AML) has completed a seven-day course of treatment with Bisantrene without any major complications. “This is…
-
Quidem voluptatibus laborum et aperiam ut sit
In vel. Quos dolorem odit voluptatem. Aut perspiciatis animi repellendus.
-
Bisantrene investigator-initiated AML trial to start in Israel
Race Oncology has announced that it has signed an agreement to conduct a trial of Race’s cancer drug, Bisantrene, at the Sheba Medical Center in Israel. The trial has been approved by the Israeli Ministry of Health and the hospital’s Research Ethics Committee, so the expectation is that the trial can start immediately. “This is…
-
Principal Investigator appointed for Bisantrene trial
Race Oncology is pleased to announce that Dr Roland Walter has agreed to be the Principal Investigator for the US registration trial for Bisantrene. Roland B. Walter, MD PhD MS, is a leading international haematologist and AML expert, based at the Fred Hutchinson Cancer Research Center in Seattle. “We are fortunate to have a global…
-
Race appoints leading haematologist to support Bisantrene
Race Oncology is pleased to announce that it has executed a consulting agreement with Professor Borje Andersson from the M.D. Anderson Cancer Research Center in Houston, Texas. Under the initial 12-month agreement, Professor Andersson will be engaged to: “I found that Race Oncology’s research strategy for developing new therapies for both paediatric and adult AML are…